High levels of Serum Angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients

Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece.
British Journal of Haematology (Impact Factor: 4.71). 09/2010; 150(5):587-91. DOI: 10.1111/j.1365-2141.2010.08288.x
Source: PubMed


Serum levels of five angiogenic cytokines were evaluated in 82 patients with primary systemic amyloidosis (AL). Angiopoietin-1, vascular endothelial growth factor, basic fibroblast growth factor and angiogenin were higher in AL patients than in controls (n = 35) and newly-diagnosed, symptomatic, myeloma patients (n = 35). Angiopoetin-1/Angiopoetin-2 ratio was lower in AL compared to controls but higher than in myeloma patients. Angiopoetin-2 correlated with cardiac dysfunction indices; however, none of the angiogenic growth factors was prognostically significant. The increased angiogenic cytokine levels observed in AL seem to represent either a toxic effect of amyloid fibrils or light chains, or a compensatory response to organ dysfunction.

Download full-text


Available from: Efstathios Kastritis,
31 Reads
  • Source
    • "Quartarone et al. [38] in their study showed a significant increase in sAng-2 levels with severity of the disease and presented a trend of correlation with β2-microglobulin levels and grade of bone involvement although their sample size was very limited. Kastritis et al. [39] in their study showed significantly higher levels of Ang-2 in MM patients as compared to controls and amyloidosis patients but they have not correlated the data with severity of the disease. Schliemann et al. have also found significantly high Ang-2 expression in the BM of patients with acute myeloid leukemia (AML) [40]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Multiple myeloma (MM) was the first hematological malignancy in which a prognostic relevance of bone marrow (BM) angiogenesis was reported. Microenvironment formed by reactive oxygen species, growth factors and chemokines initiates the process of BM angiogenesis. Among the angiopoietins, angiopoietin-1 is involved in vessel stability, whereas angiopoietin-2 is involved in vessel sprouting. Circulatory levels of angiopoietin-1, angiopoietin-2 and VEGF in 62 MM patients and 50 healthy controls were determined using ELISA. Significant increase in VEGF and angiopoietin-2 level was observed in patients which correlated positively with the severity of the disease, whereas no alteration was observed in angiopoietin-1 levels. Significant elevation in angiopoietin-2 and VEGF levels and their correlation with severity of the disease indicate their utility as potential tumor markers along with β(2)- microglobulin and might also suggest new therapeutic target for anticancer treatment.
    Clinical biochemistry 02/2011; 44(8-9):590-5. DOI:10.1016/j.clinbiochem.2011.01.010 · 2.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Clonal plasma cell dyscrasia is considered causative of both POEMS syndrome and primary light chain amyloidosis (AL-A). Patients with POEMS syndrome and AL-A may share clinical features, among which polyneuropathy, making the differential diagnosis sometimes difficult particularly in the neurological setting. Since vascular endothelial growth factor (VEGF), likely produced by the clonal plasma cell, reaches very high serum level in patients with POEMS syndrome and is considered a hallmark of the disease, we analyzed serum VEGF levels in patients with AL-A. Seventeen patients with AL-A were considered. Median VEGF level was 420 pg/ml in AL-A patients, significantly lower than in POEMS syndrome (median 2580 pg/ml, p=0.000012). Follow-up of AL-A patients showed no changes in VEGF with regard to therapy response. Serum VEGF levels were not increased in AL-A patients and did not mirror the course of the disease, therefore they may help in the differential diagnosis in cases with overlapping clinical features.
    Amyloid: the international journal of experimental and clinical investigation: the official journal of the International Society of Amyloidosis 08/2011; 18(Suppl. 1). DOI:10.3109/13506129.2011.574354039 · 2.01 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The circulating levels of several angiogenic cytokines [angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2), vascular endothelial growth factor (VEGF), angiogenin and basic fibroblast growth factor (bFGF)] were evaluated in 174 consecutive patients with newly diagnosed, symptomatic, multiple myeloma (MM). Circulating levels of Ang-1/Ang-2 were reduced in myeloma patients compared to controls, whereas VEGF and angiogenin levels were increased. Reduced angiopoietin-1/angiopoietin-2 ratio correlated with advanced disease features including international staging system (ISS)-3 stage, renal impairment and extensive bone disease. Based on immunohistochemical results in 20 patients (10 with the higher and 10 with the lower values of circulating angiopoietin-2) we found that angiopoietin-2 is expressed by myeloma cells and correlates with increased microvessel density in subsets of patients. Furthermore, Ang-1/Ang-2 ratio correlated with survival. Patients with circulating Ang-1/Ang-2 below or equal to the median value (6.03) had a median survival of 26.3 months compared to 53 months of all others (p = 0.002). Interestingly, this was mainly observed in patients who received first-line therapy with novel agent-based regimens (65% of our patients). Furthermore, a subset of ISS-3 patients with serum Ang-1/Ang-2 above the median value had favourable prognosis (median survival: 45 months versus 17 months of all others; p = 0.0001). The multivariate analysis revealed that low Ang-1/Ang-2 ratio could independently predict for inferior survival in our cohort of patients (relative risk (RR) 2.07, 95% CI 1.50-2.42; p < 0.001). These results highlight the role of angiopoietins pathway in the biology of MM and reveal novel targets for the development of antimyeloma agents.
    International Journal of Cancer 02/2012; 130(3):735-42. DOI:10.1002/ijc.26062 · 5.09 Impact Factor
Show more